Baseline characteristics of patients with below/above median %pro-ANP
| Below median %pro-ANP (<9.0%) | Above median %pro-ANP (≥9.0%) | |
| Patient number | 86 | 87 |
| Age (years) | 75 (66, 80) | 76 (68, 80) |
| Gender (female %) | 28 (33) | 32 (37) |
| BMI (kg/m²) | 24.3 (21.6, 26.6) | 22.2 (20.0, 24.8)* |
| NYHA class | ||
| Class III or IV, N (%) | 84 (98) | 80 (92) |
| Aetiology | ||
| Ischaemic, N (%) | 21 (24) | 32 (37) |
| Non-ischaemic, N (%) | 14 (16) | 24 (28) |
| Valvular, N (%) | 25 (29) | 13 (15) |
| Hypertensive, N (%) | 18 (21) | 14 (16) |
| Others, N (%) | 8 (9) | 4 (5) |
| History | ||
| HF hospitalisation, N (%) | 31 (36) | 46 (53)* |
| Hypertension, N (%) | 59 (68) | 58 (67) |
| DM, N (%) | 36 (41) | 35 (41) |
| Dyslipidaemia, N (%) | 46 (53) | 39 (45) |
| Vital signs on admission | ||
| Systolic blood pressure (mm Hg) | 138 (118, 153) | 130 (108, 159) |
| Heart rate (bpm) | 91 (73, 111) | 80 (70, 97)* |
| Echocardiography | ||
| LVDd (mm) | 54 (47, 60) | 58 (48, 67)* |
| LVDs (mm) | 40 (32, 52) | 48 (37, 60)* |
| LVEF (%) | 40 (25, 53) | 31 (20, 47)* |
| LADs (mm) | 46 (40, 51) | 50 (42, 54) |
| Laboratory data | ||
| Haemoglobin (g/dL) | 12.5 (10.4, 13.5) | 11.9 (10.6, 13.4) |
| eGFR (mL/min/1.73 m²) | 50.4 (37.2, 64.9) | 39.7 (29.7, 54.5)* |
| BUN (mg/dL) | 21 (17, 28) | 26 (20, 34)* |
| CRP (mg/dL) | 0.42 (0.17, 1.21) | 0.41 (0.10, 1.94) |
| hs-cTnT (ng/mL) | 0.030 (0.017, 0.053) | 0.040 (0.026, 0.072)* |
| Plasma aldosterone concentration (ng/dL) | 74.9 (37.1, 131.0) | 86.6 (48.9, 186.1) |
| Total plasma BNP (pmol) | 93.9 (44.1, 162.7) | 138.8 (81.1, 201.5)* |
| Cyclic GMP (pmol/mL) | 15.0 (6.4, 20.2) | 12.0 (8.4, 16.0) |
| Medications | ||
| ACEi or ARB, N (%) | 55 (64) | 52 (60) |
| Beta-blockers, N (%) | 55 (64) | 62 (71) |
| Aldosterone antagonists, N (%) | 27 (31) | 37 (43) |
| Loop diuretics, N (%) | 52 (60) | 59 (68) |
Values are the median (IQR) and patients number, N (%).
*P<0.05 vs below median %pro-ANP.
ACEi, angiotensin-converting enzyme inhibitor; ANP, atrial (A-type) natriuretic peptide; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C reactive protein; DM, diabetes mellitus; GMP, guanosine monophosphate; HF, heart failure; hs-TnT, high sensitive cardiac troponin T; LAd, left atrial diameter; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate.